Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CVRX

CVRx, Inc.

Healthcare | Medical - Devices

No licensed closing price on file for CVRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.97

CVRx, Inc. (NASDAQ: CVRX) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 12:04 UTC.

What CVRx, Inc. does

CVRx is a medical device company that develops and commercializes Barostim, an implantable neuromodulation device approved by the FDA for treating heart failure with reduced ejection fraction. The device delivers electrical pulses to baroreceptors in the carotid artery to restore balance in the autonomic nervous system and reduce symptoms of heart failure. Barostim works alongside standard pharmaceutical treatments and received FDA Breakthrough Device designation.

Summarized from CVRx, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.97
Debt/equity2.94

Revenue, margins & earnings

FY2021: net loss $43M on revenue $13M$13MFY2021FY2022: net loss $41M on revenue $22M$22MFY2022FY2023: net loss $41M on revenue $39M$39MFY2023FY2024: net loss $60M on revenue $51M$51MFY2024FY2025: net loss $53M on revenue $57M$57MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-13
  • 2026-08-13CHIEF OPERATING OFFICERPurchase26,223$76.4K
  • 2026-08-13CHIEF OPERATING OFFICERSale-1,309$3.3K
  • 2026-06-03DirectorStock Option (right to buy)Award11,182—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does CVRx, Inc. do?

CVRx is a medical device company that develops and commercializes Barostim, an implantable neuromodulation device approved by the FDA for treating heart failure with reduced ejection fraction.

When did CVRX last file with the SEC?

CVRx, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-09. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:04 UTC. This page is also available as JSON at /api/data?ticker=CVRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CVRX and 5,000+ tickers.

Create a free account — keep CVRX
For your agent
GET /api/data?ticker=CVRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt